Your session is about to expire
← Back to Search
Ziv-aflibercept + Pembrolizumab for Cancer
Study Summary
This trial is testing ziv-aflibercept given with pembrolizumab to see if it is safe and effective in treating patients with advanced solid tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had severe GI bleeding or uncontrollable blood clot issues in the last 3 months.I have a history of cancer.I am on a full dose of Coumadin for blood thinning.I haven't had any cancer, except for skin cancer, in the last 5 years.My cancer involves areas at high risk of bleeding, like the bowel or lungs.I have had a condition where my lymphocytes grow abnormally.I haven't had cancer treatment or fully recovered from its side effects in the last 4 weeks.Your hemoglobin level is at least 9 g/dL or 5.6 mmol/L.My cancer is resistant to PD-1 treatment.I have had treatment with a VEGF inhibitor for my kidney cancer.I haven't had a heart attack, severe heart issues, or stroke in the last 6 months.My kidney function is normal or only slightly below normal.I can provide a sample of my tumor, either from previous or new biopsies.Patients must have a way to measure their disease according to specific guidelines.My high blood pressure is not well-managed.I have cancer that has spread to my brain.I do not have any severe illnesses or social situations that would stop me from following the study's requirements.I had major surgery less than 4 weeks ago.I have confirmed metastatic melanoma, kidney, ovarian, or colorectal cancer.My ovarian cancer does not respond to platinum-based treatments.I have had 2 or fewer treatments for my cancer that has spread.My colorectal cancer did not respond to a treatment that included oxaliplatin.You live outside the United States.I have another cancer that is getting worse or needs treatment.I have not received a live vaccine in the last 30 days.I am 18 years old or older.You have a low count of white blood cells.Your bilirubin levels in the blood should not be too high.I agree to use birth control during the study.My cancer has spread and this was confirmed through testing.I am a woman who can have children and have a recent negative pregnancy test.I have open sores on my skin.You have had allergic reactions to drugs similar to MK-3475 and ziv-aflibercept.I have cancer cells in the fluid around my brain and spinal cord.I have been treated with specific immune-targeting medications before.Your blood clotting test results (INR or PT) should not be more than 1.5 times the normal level.I have an autoimmune disease that needed treatment in the last 3 months or have had a severe case before.Your white blood cell count is at least 1,500 per microliter.Your activated partial thromboplastin time (aPTT) test result is within 1.5 times the normal range.I am mostly self-sufficient and can carry out daily activities.You are expected to live for at least 6 more months.Your platelet count is at least 100,000 per microliter.My liver enzymes are within the required range, even with liver metastases.Your urine test shows a low amount of protein.My melanoma or kidney cancer didn't respond to previous PD-1/PD-L1 therapy.You have a diagnosed mental health condition or problems with drugs or alcohol.I haven't taken steroids or immunosuppressants in the last 7 days.
- Group 1: Treatment (pembrolizumab and ziv-aflibercept)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Ziv-Aflibercept been authorized by the Food and Drug Administration?
"Due to the preliminary nature of this medical trial, our team has rated Ziv-Aflibercept's safety a 1. This score reflects the limited data supporting both its efficacy and safety."
What is the enrollment size for this investigation?
"This trial is no longer accepting applicants. It was initially posted on March 13th 2015, and the last update occurred on November 29th 2022. Alternatively, there are 5540 sarcoma studies currently enrolling patients and 1007 trials for Ziv-Aflibercept that can be pursued."
Has Ziv-Aflibercept been the subject of prior research studies?
"Currently, 1007 studies concerning Ziv-Aflibercept are taking place. Of these, 146 have reached Phase 3. Houston is the epicenter for many of these research projects; yet 37864 sites around the world house live trials related to this drug."
What medical conditions has Ziv-Aflibercept been demonstrated to mitigate?
"Ziv-Aflibercept has been proven to be an effective treatment for malignant tumours, unresectable cases of melanoma, and microsatellite instability high."
Are there any open spots available to join this research project?
"The clinical trial hosted on clinicialtrials.gov is not currently recruiting participants, as it was posted in March 2015 and updated November 2022. Conversely, there are 6547 other trials actively searching for candidates right now."
In what capacity are these trials supervised at various sites?
"There are 8 clinical trial sites that have started recruiting patients. These include University Health Network-Princess Margaret Hospital in Toronto, Dana-Farber Cancer Institute in Boston, Moffitt Cancer Center - McKinley Campus in Bethesda and others."
Share this study with friends
Copy Link
Messenger